KR960703570A - 부형제와 함께 프로게스테론 및 폴리에틸렌글리콜을 함유하는 경구투여용 신규약제(a novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together wtth an excipient) - Google Patents

부형제와 함께 프로게스테론 및 폴리에틸렌글리콜을 함유하는 경구투여용 신규약제(a novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together wtth an excipient) Download PDF

Info

Publication number
KR960703570A
KR960703570A KR1019960700847A KR19960700847A KR960703570A KR 960703570 A KR960703570 A KR 960703570A KR 1019960700847 A KR1019960700847 A KR 1019960700847A KR 19960700847 A KR19960700847 A KR 19960700847A KR 960703570 A KR960703570 A KR 960703570A
Authority
KR
South Korea
Prior art keywords
starch
pharmaceutical composition
progesterone
composition according
polyethylene glycol
Prior art date
Application number
KR1019960700847A
Other languages
English (en)
Inventor
수잔 그람 카렌
옌센 안넬리스
Original Assignee
안네 제케르
노보 노르디스크 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안네 제케르, 노보 노르디스크 아크티에 셀스카브 filed Critical 안네 제케르
Publication of KR960703570A publication Critical patent/KR960703570A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

프로게스테론의 경구투여를 위한 약제조성물은 편리하게 PEG를 함유할 수 있고, 전분, 셀룰로스, 펙틴 및 트라가캔트로 구성된 군으로부터 선택된 부형제를 더 함유할 수 있다.

Description

부형제와 함께 프로게스테론 및 폴리에틸렌글리콜을 함유하는 경구투여용 신규약제(A NOVEL PHARMACEUTICAL FOR ORAL ADMINISTRATION COMPRISING PROGESTERONE AND A POLYETHYLENE GLYCOL TOGETHER WTTH AN EXCIPIENT)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 미분화된 프로게스테론, 폴리에틸렌글리콜, 그리고 전분, 전분성분, 변형된전분, 셀룰로스, 변형된 셀룰로스, 펙틴 및 트라가캔트로 구성된 군으로부터 선택된 부형제로 이루어진 경구투여용 약제 조성물.
  2. 제1항에 있어서, 에스트라디올을 더 포함하는 것을 특징으로 하는 약제조성물.
  3. 제1항 또는 제2항에 있어서, 프로게스테론의 양이 투약단위체당 약 10 내지 500mg의 범위내인 것을 특징으로 하는 약제조성물.
  4. 제2항 또는 제3항에 있어서, 에스트라디올의 양이 투약단위체당 약 0.1 내지 5.0mg의 범위내인 것을 특징으로 하는 약제조성물.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 옥수수전분, 감자전분, 쌀전분, 밀전분 및 타피오카전분으로 구성된 군으로부터 선택된 전분을 함유하는 것을 특징으로 하는 약제조성물.
  6. 제1항 내지 제4항 중 어느 한 항에 있어서, 아밀로스 및 아밀로펙틴으로 구성된 군으로부터 선택된 전분성분을 함유하는 것을 특징으로 하는 약제조성물.
  7. 제1항 내지 제4항 중 어느 한 항에 있어서, 변형된 전분을 함유하는 것을 특징으로 하는 약제조성물.
  8. 제1항 내지 제7항 중 어느 한 항에 있어서, 전분의 양이 투약단위체의 약 5 내지 75중량%, 더 바람직하게는 약 15 내지 50중량%, 가장 바람직하게는 약 21 내지 30중량%를 구성하는 것을 특징으로 하는 약제조성물.
  9. 다음 단계들 즉, a) 미분화된 프로게스테론을 전분, 전분성분, 변형된 전분, 셀룰로스, 변형된 셀룰로스, 펙틴 및 트라가갠트로 구성된 군으로부터 선택된 부형제와 혼합하고, 더 이상의 부형제 및 임의적으로 에스트라디올을 첨가하고, b)결합제로서 폴리에틸렌글리콜을 사용하여 과립화하고, c) 임의적으로 윤활제를 과립에 혼합하고, d) 과립을 압축하여 정제를 얻거나 과립을 캡슐에 채우는 것으로 이루어진, 향상된 생체이용률을 갖는 경구투여용 프로게스테론의 약제조성물을 만드는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960700847A 1993-08-20 1994-08-19 부형제와 함께 프로게스테론 및 폴리에틸렌글리콜을 함유하는 경구투여용 신규약제(a novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together wtth an excipient) KR960703570A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK0950/93 1993-08-20
DK93950A DK95093D0 (da) 1993-08-20 1993-08-20 Farmaceutisk formulering indeholdende et hormon
PCT/DK1994/000310 WO1995005807A1 (en) 1993-08-20 1994-08-19 A novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together with an excipient

Publications (1)

Publication Number Publication Date
KR960703570A true KR960703570A (ko) 1996-08-31

Family

ID=8099329

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700847A KR960703570A (ko) 1993-08-20 1994-08-19 부형제와 함께 프로게스테론 및 폴리에틸렌글리콜을 함유하는 경구투여용 신규약제(a novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together wtth an excipient)

Country Status (17)

Country Link
EP (1) EP0789560A1 (ko)
JP (1) JPH09501682A (ko)
KR (1) KR960703570A (ko)
CN (1) CN1132478A (ko)
AU (1) AU7530594A (ko)
BR (1) BR9407306A (ko)
CA (1) CA2169840A1 (ko)
CZ (1) CZ42596A3 (ko)
DK (1) DK95093D0 (ko)
FI (1) FI960749A (ko)
HU (1) HUT74167A (ko)
LT (1) LT4043B (ko)
NO (1) NO960653D0 (ko)
NZ (1) NZ271617A (ko)
PL (1) PL313113A1 (ko)
SK (1) SK19396A3 (ko)
WO (1) WO1995005807A1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772617B1 (fr) * 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
FR2775599B1 (fr) * 1998-03-09 2001-08-17 Besins Iscovesco Lab Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation
GB2339114B (en) * 1998-06-30 2003-03-05 Ericsson Telefon Ab L M Secure messaging in mobile telephones
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
JP4354667B2 (ja) * 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
FI20002768A (fi) * 2000-12-18 2002-06-19 Licentia Oy Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
AU2002242339A1 (en) * 2002-03-14 2003-09-29 Watson Pharmaceuticals, Inc. Progesterone oral drug delivery system
AU2004234057A1 (en) * 2003-04-29 2004-11-11 Akzo Nobel N.V. Antisolvent solidification process
AU2006287925B2 (en) 2005-04-28 2012-03-01 Wyeth Compositions containing micronized tanaproget
EP2055306A1 (de) * 2007-11-05 2009-05-06 Bayer Schering Pharma AG Verwendung eines Gestagens in Kombination mit einem Estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/Trägern zur laktosefreien oralen Kontrazeption
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
BR112017027688A2 (pt) 2015-06-22 2018-09-04 Lipocine Inc Composições orais que contêm éster de 17- hidroxiprogesterona e métodos relacionados
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862311A (en) * 1971-04-12 1975-01-21 Ciba Geigy Corp Novel method of enhancing progestational endometrial proliferation with progesterone
FR2408345A1 (fr) 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
GB2091552A (en) 1980-09-09 1982-08-04 Carnrick G W Ltd Use of progesterone for the treatment of post-menopausal women
US4963540A (en) * 1986-04-16 1990-10-16 Maxson Wayne S Method for treatment of premenstrual syndrome
US5084277A (en) 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
US5116619A (en) 1988-08-30 1992-05-26 Lee Roy Morgan Vaginal progesterone tablet
WO1990008537A1 (en) * 1989-02-06 1990-08-09 Abbott Laboratories Pharmaceutical compositions for oral administration
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions

Also Published As

Publication number Publication date
CA2169840A1 (en) 1995-03-02
DK95093D0 (da) 1993-08-20
NO960653L (no) 1996-02-19
AU7530594A (en) 1995-03-21
LT4043B (en) 1996-09-25
PL313113A1 (en) 1996-06-10
EP0789560A1 (en) 1997-08-20
SK19396A3 (en) 1997-03-05
HU9600376D0 (en) 1996-04-29
HUT74167A (en) 1996-11-28
FI960749A0 (fi) 1996-02-19
BR9407306A (pt) 1996-10-08
NZ271617A (en) 1996-11-26
FI960749A (fi) 1996-02-19
WO1995005807A1 (en) 1995-03-02
NO960653D0 (no) 1996-02-19
JPH09501682A (ja) 1997-02-18
LT96010A (ko) 1996-06-25
CZ42596A3 (en) 1996-06-12
CN1132478A (zh) 1996-10-02

Similar Documents

Publication Publication Date Title
KR960703570A (ko) 부형제와 함께 프로게스테론 및 폴리에틸렌글리콜을 함유하는 경구투여용 신규약제(a novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together wtth an excipient)
KR870003781A (ko) 지효성 조성물
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
HUP0100818A2 (hu) Térhálós, magas amilóztartalmú, funkcionális csoportokkal rendelkező keményítő, mint gyógyszer hatóanyagok lassú kibocsátását biztosító mátrix
UY24875A1 (es) Composiciones farmacéuticas conteniendo tetrahidrolipstatina
KR880701099A (ko) 경구 투여용 서방출형제제
CA2149362A1 (en) Pharmaceutical composition based on guar gum coated with simethicone, inassociation with a neutralizing antacid
JP2002012559A5 (ko)
KR890001526A (ko) 경구용 서방성 아세트 아미노펜 제형 및 이의 제조방법
WO1992009274A1 (en) High amylose starch substituted gelatin capsules
KR860002270A (ko) 니트렌디핀을 함유하는 고상 약제 및 그의 제조방법
FR2729857B1 (fr) Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
PT975348E (pt) Composicoes de tibolona estabilizadas
RU99121407A (ru) Стабилизированные композиции тиболона
JP2000044465A (ja) 軟カプセル剤
JPH06321790A (ja) 速崩壊性生薬製剤
US5198228A (en) Direct dry compressible acetaminophen tablet
US5230901A (en) Sustained release tablet of a mixture of alginates and polyacrylates
IE903330A1 (en) An analgesic composition and a method for its formulation
KR930021206A (ko) 시타라빈 옥포스페이트 경질 캡슐제
HUP9800395A3 (en) Sulfonamide-substituted benzoxepine derivatives, their use as medicines and pharmaceutical compositions containing them
EA200701091A1 (ru) Противозачаточный фармацевтический препарат
KR890001559A (ko) 트라피딜을 함유하는 제약 조성물, 그의 제조방법 및 관련된 치료 용도
JPS567713A (en) Oily main drug preparation composition
KR950016756A (ko) 피로회복제 조성물

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid